XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	0,024	0,035	19:17
	0,024	0,029	18:15

Realtime

Geld

Brief

Zeit

0,024

0,035

19:17

0,024

0,029

18:15

XFRA CAPITAL ADJUSTMENT INFORMATION - 05.12.2023

Das Instrument 8QE KYG2007L2040 CAZOO GROUP A DL-,0001 EQUITY wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023
The instrument 8QE KYG2007L2040 CAZOO GROUP A DL-,0001 EQUITY is traded cum capital adjustment on 05.12.2023 and ex capital adjustment on 06.12.2023

Das Instrument SCP GB00B63D3314 SCANCELL HLDGS LS -,001 EQUITY wird ex Kapitalmassnahme gehandelt am 05.12.2023
The instrument SCP GB00B63D3314 SCANCELL HLDGS LS -,001 EQUITY is traded ex capital adjustment on 05.12.2023

Das Instrument IEG9 LU0546688564 GS GLHLTHCAREEQ PCEOHII INVESTMENT FUND wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023
The instrument IEG9 LU0546688564 GS GLHLTHCAREEQ PCEOHII INVESTMENT FUND is traded cum capital adjustment on 05.12.2023 and ex capital adjustment on 06.12.2023

Das Instrument SDL AU000000FYI5 FYI RESOURCES LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023
The instrument SDL AU000000FYI5 FYI RESOURCES LTD. EQUITY is traded cum capital adjustment on 05.12.2023 and ex capital adjustment on 06.12.2023

Das Instrument IEGB LU0341736568 GS GLHLTHCAREEQ PCEO INVESTMENT FUND wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023
The instrument IEGB LU0341736568 GS GLHLTHCAREEQ PCEO INVESTMENT FUND is traded cum capital adjustment on 05.12.2023 and ex capital adjustment on 06.12.2023

Das Instrument 54Z FR0013399359 ENERGISME S.A. EO-,10 EQUITY wird ex Kapitalmassnahme gehandelt am 05.12.2023
The instrument 54Z FR0013399359 ENERGISME S.A. EO-,10 EQUITY is traded ex capital adjustment on 05.12.2023

Das Instrument K0B0 SE0019070749 RIGHTBRIDGE VENTURES GRP EQUITY wird ex Kapitalmassnahme gehandelt am 05.12.2023
The instrument K0B0 SE0019070749 RIGHTBRIDGE VENTURES GRP EQUITY is traded ex capital adjustment on 05.12.2023

Das Instrument 8V8 NO0010692130 GENETIC ANALYSIS NK -,60 EQUITY wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023
The instrument 8V8 NO0010692130 GENETIC ANALYSIS NK -,60 EQUITY is traded cum capital adjustment on 05.12.2023 and ex capital adjustment on 06.12.2023

Das Instrument 1TB DK0060910917 ORPHAZYME A/S DK 1 EQUITY wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023
The instrument 1TB DK0060910917 ORPHAZYME A/S DK 1 EQUITY is traded cum capital adjustment on 05.12.2023 and ex capital adjustment on 06.12.2023

Treibt Nvidias KI-Boom den Uranpreis?

In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.

Hier klicken

Zeit	Aktuelle Nachrichten
07.11.	CADOUX LIMITED: Results of Meeting
07.11.	CADOUX LIMITED: AGM Presentation
31.10.	CADOUX LIMITED: Change of Director's Interest Notice
31.10.	CADOUX LIMITED: Notification of cessation of securities - CCM
29.10.	CADOUX LIMITED: Quarterly Activities/Appendix 5B Cash Flow Report

Zeit

Aktuelle Nachrichten

07.11.

CADOUX LIMITED: Results of Meeting

07.11.

CADOUX LIMITED: AGM Presentation

31.10.

CADOUX LIMITED: Change of Director's Interest Notice

31.10.

CADOUX LIMITED: Notification of cessation of securities - CCM

29.10.

CADOUX LIMITED: Quarterly Activities/Appendix 5B Cash Flow Report

Zeit	Aktuelle Nachrichten
17.07.	Why this British tech company is succeeding where Cazoo failed
16.07.	Cazoo racked up debts of over £260m as it collapsed into administration
03.07.	Cazoo Group Ltd - 6-K, Report of foreign issuer
21.06.	Cazoo Group Ltd - 6-K, Report of foreign issuer
09.06.	Motors.co.uk lines up deal to buy stricken car marketplace Cazoo

Zeit

Aktuelle Nachrichten

17.07.

Why this British tech company is succeeding where Cazoo failed

16.07.

Cazoo racked up debts of over £260m as it collapsed into administration

03.07.

Cazoo Group Ltd - 6-K, Report of foreign issuer

21.06.

Cazoo Group Ltd - 6-K, Report of foreign issuer

09.06.

Motors.co.uk lines up deal to buy stricken car marketplace Cazoo

Zeit	Aktuelle Nachrichten
05.12.23	XFRA CAPITAL ADJUSTMENT INFORMATION - 05.12.2023		Das Instrument 8QE KYG2007L2040 CAZOO GROUP A DL-,0001 EQUITY wird cum Kapitalmassnahme gehandelt am 05.12.2023 und ex Kapitalmassnahme am 06.12.2023 The instrument 8QE KYG2007L2040 CAZOO GROUP A DL-... ► Artikel lesen

Zeit

Aktuelle Nachrichten

05.12.23

XFRA CAPITAL ADJUSTMENT INFORMATION - 05.12.2023

Zeit	Aktuelle Nachrichten
08.08.	GENETIC ANALYSIS AS: Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology
17.07.	Genetic Analysis AS: Minutes from the Extraordinary General Meeting 17 July 2024
15.07.	GENETIC ANALYSIS AS: Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
04.07.	Genetic Analysis AS: Mandatory notification of trade - Primary Insider
03.07.	Genetic Analysis AS: Notice of Extraordinary General Meeting 2024

Zeit

Aktuelle Nachrichten

08.08.

GENETIC ANALYSIS AS: Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology

17.07.

Genetic Analysis AS: Minutes from the Extraordinary General Meeting 17 July 2024

15.07.

GENETIC ANALYSIS AS: Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises

04.07.

Genetic Analysis AS: Mandatory notification of trade - Primary Insider

03.07.

Genetic Analysis AS: Notice of Extraordinary General Meeting 2024

Zeit	Aktuelle Nachrichten
28.10.	RIGHTBRIDGE VENTURES GROUP AB: Rightbridge Ventures Group and Oceanview Announce Mutual Termination of Share Purchase Agreement - Claes Kalborg reinstated as CEO
10.09.	RIGHTBRIDGE VENTURES GROUP AB: Rightbridge Ventures Appoints Mangold as Liquidity Provider
30.08.	RIGHTBRIDGE VENTURES GROUP AB: Rightbridge Ventures Group Announces Appointment of Thiago de Freitas as New CEO, Aiming for Strategic Growth and Market Expansion
30.08.	RIGHTBRIDGE VENTURES GROUP AB: RIGHTBRIDGE VENTURES GROUP INTERIM REPORT SECOND QUARTER 2024
24.06.	Subscription Warrants of Series TO2 Subscribed to 63.5 Percent and Rightbridge Ventures Group AB (publ) Receives APPROX SEK 1.3 Million After Offsetting Debts of SEK 3.5 Million

Zeit

Aktuelle Nachrichten

28.10.

RIGHTBRIDGE VENTURES GROUP AB: Rightbridge Ventures Group and Oceanview Announce Mutual Termination of Share Purchase Agreement - Claes Kalborg reinstated as CEO

10.09.

RIGHTBRIDGE VENTURES GROUP AB: Rightbridge Ventures Appoints Mangold as Liquidity Provider

30.08.

RIGHTBRIDGE VENTURES GROUP AB: Rightbridge Ventures Group Announces Appointment of Thiago de Freitas as New CEO, Aiming for Strategic Growth and Market Expansion

30.08.

RIGHTBRIDGE VENTURES GROUP AB: RIGHTBRIDGE VENTURES GROUP INTERIM REPORT SECOND QUARTER 2024

24.06.

Subscription Warrants of Series TO2 Subscribed to 63.5 Percent and Rightbridge Ventures Group AB (publ) Receives APPROX SEK 1.3 Million After Offsetting Debts of SEK 3.5 Million

Zeit	Aktuelle Nachrichten
Mo	Scancell Hlds - Positive data from Phase 2 SCOPE trial with SCIB1
26.10.	EXECUTIVE CHANGES: New Scancell, Nanoco and LPA CEOs; Coral CEO exits
25.10.	Scancell Hlds - Result of Annual General Meeting
22.10.	Scancell Appoints Phil L'Huillier As CEO
22.10.	Scancell Hlds - Scancell Appoints Dr Phil L'Huillier as CEO

Zeit

Aktuelle Nachrichten

Scancell Hlds - Positive data from Phase 2 SCOPE trial with SCIB1

26.10.

EXECUTIVE CHANGES: New Scancell, Nanoco and LPA CEOs; Coral CEO exits

25.10.

Scancell Hlds - Result of Annual General Meeting

22.10.

Scancell Appoints Phil L'Huillier As CEO

22.10.

Scancell Hlds - Scancell Appoints Dr Phil L'Huillier as CEO

Zeit	Aktuelle Nachrichten
24.10.	Nasdaq Welcomes Strategic Partners A/S to Nasdaq Copenhagen Main Market	Copenhagen, October 24, 2024?- Nasdaq (Nasdaq: NDAQ) announces that trading in Strategic Partners shares (ticker name: STRAP) will commence today on the Nasdaq Copenhagen Main Market. Strategic Partners... ► Artikel lesen
22.10.	Nasdaq Copenhagen A/S: Orphazyme A/S - name change to Strategic Partners A/S	The changes below will take effect on Nasdaq Copenhagen as per 24 October 2024. ISIN: DK0062502894 ------------------------------------------- Name Orphazyme ------------------------------------------- New... ► Artikel lesen
23.09.	First North Denmark: Orphazyme A/S - admittance to trading and official listing of new shares	The share capital of Orphazyme A/S has been increased due to a directed issue. The admittance to trading and official listing will take effect as per 24 September 2024 in the ISIN below. ISIN: ... ► Artikel lesen
23.09.	Nasdaq Copenhagen A/S: Orphazyme A/S - Observation status removed	Nasdaq Copenhagen has today removed observation status for: ISIN Name DK0062502894 ORPHAZYME The company's observation status is removed because the company's change of identity... ► Artikel lesen

Zeit

Aktuelle Nachrichten

24.10.

Nasdaq Welcomes Strategic Partners A/S to Nasdaq Copenhagen Main Market

Copenhagen, October 24, 2024?- Nasdaq (Nasdaq: NDAQ) announces that trading in Strategic Partners shares (ticker name: STRAP) will commence today on the Nasdaq Copenhagen Main Market. Strategic Partners...
► Artikel lesen

22.10.

Nasdaq Copenhagen A/S: Orphazyme A/S - name change to Strategic Partners A/S

The changes below will take effect on Nasdaq Copenhagen as per 24 October 2024. ISIN: DK0062502894 ------------------------------------------- Name Orphazyme ------------------------------------------- New...
► Artikel lesen

23.09.

First North Denmark: Orphazyme A/S - admittance to trading and official listing of new shares

The share capital of Orphazyme A/S has been increased due to a directed issue. The admittance to trading and official listing will take effect as per 24 September 2024 in the ISIN below. ISIN: ...
► Artikel lesen

23.09.

Nasdaq Copenhagen A/S: Orphazyme A/S - Observation status removed

Nasdaq Copenhagen has today removed observation status for: ISIN Name DK0062502894 ORPHAZYME The company's observation status is removed because the company's change of identity...
► Artikel lesen

Unternehmen / Aktien	Kurs	%
CADOUX LIMITED	0,024	-22,95 %
CAZOO GROUP LTD	0,354	0,00 %
ENERGISME SA	0,001	+33,33 %
GENETIC ANALYSIS AS	0,033	0,00 %
RIGHTBRIDGE VENTURES GROUP AB	0,001	0,00 %
SCANCELL HOLDINGS PLC	0,145	0,00 %
STRATEGIC PARTNERS A/S	124,00	0,00 %

Unternehmen / Aktien

Kurs

CADOUX LIMITED

0,024

-22,95 %

CAZOO GROUP LTD

0,354

0,00 %

ENERGISME SA

0,001

+33,33 %

GENETIC ANALYSIS AS